Mechanisms and pharmacology of neuropathic pain in multiple sclerosis

Current Topics in Behavioral Neurosciences

Volumn 20, Issue , 2014, Pages 75-97

  Iannitti, T ^a   Kerr, B J ^b   Taylor, B K ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; Pain

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; CANNABINOID 2 RECEPTOR AGONIST; CANNABIS; CARBAMAZEPINE; CEFTRIAXONE; DULOXETINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MORPHINE; MUSCLE RELAXANT AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NABIXIMOLS; NALOXONE; NORTRIPTYLINE; RAPAMYCIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CLINICAL FEATURE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); COLD SENSITIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HEAT HYPERSENSITIVITY; HUMAN; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL SENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY DEFENSIVENESS; SEX DIFFERENCE; THEILER'S MURINE ENCEPHALOMYELITIS VIRUS;

EID: 84922064311     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2014_288     Document Type: Article

References (139)

1. Aicher SA, Silverman MB, Winkler CW, Bebo BF Jr (2004) Hyperalgesia in an animal model of multiple sclerosis. Pain 110:560-570
2. Al-Araji AH, Oger J (2005) Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler 11:398-402
3. Anderton SM, Liblau RS (2008) Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 21:248-254
4. Asante CO, Wallace VC, Dickenson AH (2010) Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat. J Pain: Official J Am Pain Soc 11:1356-1367
5. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, European Federation of Neurological S (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol: Official J Eur Fed Neurol Soc 17:1113-e1188
6. Bastianello S, Paolillo A, Giugni E, Giuliani S, Evangelisti G, Luccichenti G, Angeloni U, Colonnese C, Salvetti M, Gasperini C, Pozzilli C, Fieschi C (2000) MRI of spinal cord in MS. J Neurovirol 6(Suppl 2):S130-133
7. Bauer J, Sminia T, Wouterlood FG, Dijkstra CD (1994) Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 38:365-375
8. Baxter AG (2007) The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7:904-912
9. Beard S, Hunn A, Wight J (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 7:iii, ix-x, 1-111
10. Ben-Zacharia AB (2011) Therapeutics for multiple sclerosis symptoms. Mount Sinai J Med New York 78:176-191
11. Berard JL, Wolak K, Fournier S, David S (2010) Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58:434-445
12. Boissy AR, Cohen JA (2007) Multiple sclerosis symptom management. Expert Rev Neurother 7:1213-1222
13. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK (2007) A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 29:2022-2030
14. Calabrese M, Favaretto A, Martini V, Gallo P (2012) Grey matter lesions in MS: From histology to clinical implications. Prion 7
15. Castro AR, Pinto M, Lima D, Tavares I (2004) Nociceptive spinal neurons expressing NK1 and GABAB receptors are located in lamina I. Brain Res 1003:77-85
16. Chitsaz A, Janghorbani M, Shaygannejad V, Ashtari F, Heshmatipour M, Freeman J (2009) Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain 25:281-285
17. Constantinescu CS, Farooqi N, O'Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164:1079-1106
18. Conte A, Bettolo CM, Onesti I, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M (2009) Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 13:472-477
19. Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B (2012) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ : Can Med Assoc J = Journal de l'Association medicale canadienne 184:1143-1150
20. Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, Ebers GC (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122(Pt 4):625-639 (A Journal of Neurology)
21. Croxford AL, Kurschus FC, Waisman A (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 1812:177-183
22. Cruccu G, Aminoff MJ, Curio G, Guerit JM, Kakigi R, Mauguiere F, Rossini PM, Treede RD, Garcia-Larrea L (2008) Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 119:1705-1719 Official Journal of the International Federation of Clinical Neurophysiology
23. Cruccu G, Biasiotta A, Di Rezze S, Fiorelli M, Galeotti F, Innocenti P, Mameli S, Millefiorini E, Truini A (2009) Trigeminal neuralgia and pain related to multiple sclerosis. Pain 143:186-191
24. Cruccu G, Garcia-Larrea L (2004) Clinical utility of pain-laser evoked potentials. Suppl Clin Neurophysiol 57:101-110
25. D'Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J (2011) Vascular aspects of multiple sclerosis. Lancet Neurol 10:657-666
26. Darabi K, Karulin AY, Boehm BO, Hofstetter HH, Fabry Z, LaManna JC, Chavez JC, Tary-Lehmann M, Lehmann PV (2004) The third signal in T cell-mediated autoimmune disease? J Immunol 173:92-99
27. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:S3-14
28. EliLilly&Co (2011) Duloxetine for multiple sclerosis pain [Clinical-Trials.gov identifier NCT00755807]. US National Institutes of Health, ClinicalTrialsgov http://www.clinicaltrials. gov
29. Falah M, Madsen C, Holbech JV, Sindrup SH (2011) A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain
30. Flensner G, Ek AC, Soderhamn O, Landtblom AM (2011) Sensitivity to heat in MS patients: a factor strongly influencing symptomology-an explorative survey. BMC Neurol 11:27
31. Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, Macleod MR, Fallon MT (2012) Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain
32. Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ (2012) Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 8:624-634
33. Fuller KG, Olson JK, Howard LM, Croxford JL, Miller SD (2004) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Med 102:339-361
34. Garcia-Lorenzo D, Francis S, Narayanan S, Arnold DL, Collins DL (2012) Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging. Med Image Anal
35. Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, Lumb BM, Hunt SP (2009) A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci 29:15017-15027 The Official Journal of the Society for Neuroscience
36. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971 A Journal of Neurology
37. Goverman J (2009) Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9:393-407
38. Grau-Lopez L, Sierra S, Martinez-Caceres E, Ramo-Tello C (2011) Analysis of the pain in multiple sclerosis patients. Neurologia 26:208-213
39. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko TJ, Rice AS, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD (2011) NeuPSIG guidelines on neuropathic pain assessment. Pain 152:14-27
40. Haberland C (2007) Clinical neuropathology: text and color Atlas New York. Demos Medical Publishing, New York
41. Handel AE, Lincoln MR, Ramagopalan SV (2011) Of mice and men: experimental autoimmune encephalitis and multiple sclerosis. Eur J Clin Invest 41:1254-1258
42. Hansen C, Hopf HC, Treede RD (1996) Paradoxical heat sensation in patients with multiple sclerosis. Evidence for a supraspinal integration of temperature sensation. Brain 119 (Pt 5):1729-1736 (A Journal of Neurology)
43. Herman RM, D'Luzansky SC, Ippolito R (1992) Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain 8:338-345
44. Hofstetter HH, Shive CL, Forsthuber TG (2002) Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 169:117-125
45. Houtchens MK, Richert JR, Sami A, Rose JW (1997) Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 3:250-253
46. Hu W, Lucchinetti CF (2009) The pathological spectrum of CNS inflammatory demyelinating diseases. Seminars Immunopathol 31:439-453
47. Huseby ES, Huseby PG, Shah S, Smith R, Stadinski BD (2012) Pathogenic CD8 T cells in multiple sclerosis and its experimental models. Front Immunol 3:64
48. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C (2001) T-and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36:220-234
49. Invernizzi P, Bertolasi L, Bianchi MR, Turatti M, Gajofatto A, Benedetti MD (2011) Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. J Neurol 258:1933-1939
50. Iuliano G, Napoletano R, Esposito A (2008) Multiple sclerosis: relapses and timing of remissions. Eur Neurol 59:44-48
51. Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 6 Suppl A:61-68
52. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, Treede RD (2011) A new definition of neuropathic pain. Pain 152:2204-2205
53. Jones MV, Nguyen TT, Deboy CA, Griffin JW, Whartenby KA, Kerr DA, Calabresi PA (2008) Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol 199:83-93
54. Kakigi R, Kuroda Y, Neshige R, Endo C, Shibasaki H (1992) Physiological study of the spinothalamic tract conduction in multiple sclerosis. J Neurol Sci 107:205-209
55. Kalman S, Osterberg A, Sorensen J, Boivie J, Bertler A (2002) Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain 6:69-80
56. Kanchandani R, Howe JG (1982) Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature. J Neurol Neurosurg Psychiatry 45:308-312
57. Khan N, Smith MT (2013) Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodentEAEmodels. Inflammopharmacology
58. Kieseier BC, Hartung HP (2003) Current disease-modifying therapies in multiple sclerosis. Semin Neurol 23:133-146
59. Kuerten S, Gruppe TL, Laurentius LM, Kirch C, Tary-Lehmann M, Lehmann PV, Addicks K (2011) Differential patterns of spinal cord pathology induced by MP4, MOG peptide 35-55, and PLP peptide 178-191 in C57BL/6 mice. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 119:336-346
60. Kumpfel T, Hoffmann LA, Pollmann W, Rieckmann P, Zettl UK, Kuhnbach R, Borasio GD, Voltz R (2007) Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med 21:109-114
61. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260:984-997
62. Lassmann H (1983) Chronic relapsing experimental allergic encephalomyelitis: its value as an experimental model for multiple sclerosis. J Neurol 229:207-220
63. Lassmann H (2010) Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol 225:2-8
64. Li H, Cuzner ML, Newcombe J (1996) Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl Neurobiol 22:207-215
65. Li WW, Setzu A, Zhao C, Franklin RJ (2005) Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a nonimmune model of demyelination. J Neuroimmunol 158:58-66
66. Linker RA, Lee DH (2009) Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Trans Stroke Med 1:5
67. Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, Feinstein DL, Dello Russo C (2012) Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. J Neuroimmunol 243:43-51
68. Lu J, Kurejova M, Wirotanseng LN, Linker RA, Kuner R, Tappe-Theodor A (2012) Pain in experimental autoimmune encephalitis: a comparative study between different mouse models. J Neuroinflam 9:233
69. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 46:907-911
70. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
71. Luque FA, Jaffe SL (2007) Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol 79:341-356
72. Lynch JL, Alley JF, Wellman L, Beitz AJ (2008) Decreased spinal cord opioid receptor mRNA expression and antinociception in a Theiler's murine encephalomyelitis virus model of multiple sclerosis. Brain Res 1191:180-191
73. Margeta-Mitrovic M, Mitrovic I, Riley RC, Jan LY, Basbaum AI (1999) Immunohistochemical localization of GABA(B) receptors in the rat central nervous system. J Comp Neurol 405:299-321
74. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
75. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, Brochet B, Canron MH, Franconi JM, Boiziau C, Petry KG (2011) Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 17:2-15
76. Miller E (2011) Multiple sclerosis: Landes bioscience and Springer Science ? Business Media
77. Mix E, Meyer-Rienecker H, Hartung HP, Zettl UK (2010) Animal models of multiple sclerosis-potentials and limitations. Prog Neurobiol 92:386-404
78. Mondino A, Mueller DL (2007) mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 19:162-172
79. Morin C, Bushnell MC, Luskin MB, Craig AD (2002) Disruption of thermal perception in a multiple sclerosis patient with central pain. Clin J Pain 18:191-195
80. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, Smith T (2008) Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18:52-61
81. Norsted Gregory E, Codeluppi S, Gregory JA, Steinauer J, Svensson CI (2010) Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. Neuroscience 169:1392-1402
82. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C (2004) Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59:440-452
83. Nurmikko TJ (2009) Pathophysiology of MS-related trigeminal neuralgia. Pain 143:165-166
84. Nurmikko TJ, Gupta S, Maclver K (2010) Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep 14:189-195
85. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH (2008) Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 137:96-111
86. Olechowski CJ, Parmar A, Miller B, Stephan J, Tenorio G, Tran K, Leighton J, Kerr BJ (2010) A diminished response to formalin stimulation reveals a role for the glutamate transporters in the altered pain sensitivity of mice with experimental autoimmune encephalomyelitis (EAE). Pain 149:565-572
87. Olechowski CJ, Tenorio G, Sauve Y, Kerr BJ (2013) Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE). Exp Neurol 241C:113-121
88. Olechowski CJ, Truong JJ, Kerr BJ (2009) Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 141:156-164
89. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD (2004) Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev 17:174-207
90. Olson JK, Ercolini AM, Miller SD (2005) A virus-induced molecular mimicry model of multiple sclerosis. Curr Top Microbiol Immunol 296:39-53
91. Ossipov MH, Zhang ET, Carvajal C, Gardell L, Quirion R, Dumont Y, Lai J, Porreca F (2002) Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y. J Neurosci 22:9858-9867 The Official Journal of the Society for Neuroscience
92. Osterberg A, Boivie J (2010) Central pain in multiple sclerosis-sensory abnormalities. Eur J Pain 14:104-110
93. Osterberg A, Boivie J, Thuomas KA (2005) Central pain in multiple sclerosis-prevalence and clinical characteristics. Eur J Pain 9:531-542
94. Pender MP (1988) The pathophysiology of myelin basic protein-induced acute experimental allergic encephalomyelitis in the Lewis rat. J Neurol Sci 86:277-289
95. Pender MP, Scurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R (2014) Mult Scler [Epub ahead of print]
96. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292-302
97. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 58:840-846
98. Price GW, Kelly JS, Bowery NG (1987) The location of GABAB receptor binding sites in mammalian spinal cord. Synapse 1:530-538
99. Ragonese P, Aridon P, Salemi G, D'Amelio M, Savettieri G (2008) Mortality in multiple sclerosis: a review. Eur J Neurol 15:123-127 The Official Journal of the European Federation of Neurological Societies
100. Ramos KM, Lewis MT, Morgan KN, Crysdale NY, Kroll JL, Taylor FR, Harrison JA, Sloane EM, Maier SF, Watkins LR (2010) Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience 169:1888-1900
101. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL (2004) Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10:589-595
102. Rodrigues DH, Sachs D, Teixeira AL (2009) Mechanical hypernociception in experimental autoimmune encephalomyelitis. Arq Neuropsiquiatr 67:78-81
103. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabisbased medicine in central pain in multiple sclerosis. Neurology 65:812-819
104. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29:2068-2079
105. Rossi S, Mataluni G, Codeca C, Fiore S, Buttari F, Musella A, Castelli M, Bernardi G, Centonze D (2009) Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 16:360-366 The Official Journal of the European Federation of Neurological Societies
106. Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234-246
107. Sakai T, Tomiyasu S, Ono T, Yamada H, Sumikawa K (2004) Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. Clin J Pain 20:375-376
108. Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V (2003) Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60:1082-1088
109. Schwendimann RN, Alekseeva N (2007) Gender issues in multiple sclerosis. Int Rev Neurobiol 79:377-392
110. Singhal D, Berger JR (2012) Detecting multiple sclerosis mimics early. Fut Neurol 7(5):547-555
111. Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA (2004) Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler 10:679-685
112. Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, Gasperini C, Ghezzi A, Martinelli V, Milanese C, Patti F, Trojano M, Verdun E, Mancardi GL, Pa IMSSG (2004) The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 63:919-921
113. Solaro C, Messmer Uccelli M (2010) Pharmacological management of pain in patients with multiple sclerosis. Drugs 70:1245-1254
114. Solaro C, Restivo D, Mancardi GL, Tanganelli P (2007) Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol sci 28:156-158 Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
115. Solaro C, Uccelli MM (2011) Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol 7:519-527
116. Spiegel J, Hansen C, Baumgartner U, Hopf HC, Treede RD (2003) Sensitivity of laser-evoked potentials versus somatosensory evoked potentials in patients with multiple sclerosis. Clin Neurophysiol 114:992-1002 Official Journal of the International Federation of Clinical Neurophysiology
117. Steinman L, Zamvil SS (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12-21
118. Stenager E, Knudsen L, Jensen K (1991) Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 84:197-200
119. Stenager E, Knudsen L, Jensen K (1995) Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. Ital J Neurol Sci 16:629-632
120. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694
121. Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329:253
122. Svendsen KB, Jensen TS, Hansen HJ, Bach FW (2005) Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 114:473-481
123. Thibault K, Calvino B, Pezet S (2011) Characterisation of sensory abnormalities observed in an animal model of multiple sclerosis: a behavioural and pharmacological study. Eur J Pain 15(231):e231-216
124. Thorpe JW, Kidd D, Moseley IF, Thompson AJ, MacManus DG, Compston DA, McDonald WI, Miller DH (1996) Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 119(Pt 3):709-714 A Journal of Neurology
125. Treede RD, Lorenz J, Baumgartner U (2003) Clinical usefulness of laser-evoked potentials. Neurophysiologie clinique =. Clin Neurophysiol 33:303-314
126. Truini A, Barbanti P, Pozzilli C, Cruccu G (2012) A mechanism-based classification of pain in multiple sclerosis. J Neurol
127. Truini A, Galeotti F, Cruccu G (2011) Treating pain in multiple sclerosis. Exp Opin Pharmacother 12:2355-2368
128. Tsunoda I, Fujinami RS (2010) Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J Neuroimmune Pharmacol 5:355-369 The Official Journal of the Society on NeuroImmune Pharmacology
129. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, Tribolo A, Capello E, Mancardi GL, Mutani R, Giordana MT, Cavalla P (2009) Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 68:489-502
130. Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434-441
131. Wade DT, Makela PM, House H, Bateman C, Robson P (2006) Long-term use of a cannabisbased medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12:639-645
132. Wekerle H (2008) Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 67 Suppl 3:iii56-60
133. Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50:169-180
134. Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD (2006) Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 253:1337-1341
135. Wu M, Tsirka SE (2009) Endothelial NOS-deficient mice reveal dual roles for nitric oxide during experimental autoimmune encephalomyelitis. Glia 57:1204-1215
136. Yuan S, Shi Y, Tang SJ (2012) Wnt signaling in the pathogenesis of multiple sclerosis-associated chronic pain. J Neuroimmune Pharmacol (The Official Journal of the Society on Neuro-Immune Pharmacology)
137. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517-1526
138. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, Group MR (2012) Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiat 83:1125-1132
139. Zhang Z, Zhang ZY, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ (2011) Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. J Neuroimmunol 237:73-79